ASCO® 2024 Insights: "Study EV-103 - Neoadjuvant Enfortumab Vedotin in Cisplatin-Ineligible MIBC Patients" | VuMedi

Find latest Bladder Cancer videos · 200+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Study EV-103 - Neoadjuvant Enfortumab Vedotin in Cisplatin-Ineligible MIBC Patients"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Nataliya Mar

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Nataliya Mar

142 views

June 21, 2024

Comments 0

Login to view comments. Click here to Login